A µ-opioid receptor superagonist analgesic with minimal adverse effects
Article Date: 01 April 2026
Article URL: https://www.nature.com/articles/s41586-026-10299-9
Article Image: Figure 1
Summary
This Nature paper describes the discovery and preclinical characterisation of two closely related fluorinated nitazene compounds — FNZ (fluornitrazene) and its major metabolite DFNZ — that are highly selective superagonists at the µ-opioid receptor (MOR). The team combined medicinal chemistry, binding and kinetic assays, cryo-electron microscopy, proteomics, in vivo pharmacokinetics and an extensive battery of rodent behavioural and neurophysiological tests to compare the compounds with standard MOR agonists.
Key findings: FNZ is a potent MOR superagonist with rapid brain entry and strong effects on G-protein and β-arrestin pathways; it is quickly metabolised to DFNZ. DFNZ retains MOR superagonism in vitro but shows poorer brain penetrance because it is a substrate for P-glycoprotein (PGP) and BCRP efflux transporters. Paradoxically, despite high intrinsic efficacy in cell assays, DFNZ produces robust analgesia in rodents with markedly reduced respiratory depression, weak withdrawal and low reinforcement liability. DFNZ also decreases heroin self-administration in rats and produces limited phasic dopamine responses in nucleus accumbens — a possible mechanism for its lower abuse potential.
The authors present a 2.3 Å cryo-EM structure of FNZ bound to the MOR–G i complex, map ligand–receptor interactions that underlie MOR selectivity, and use APEX proximity proteomics to show DFNZ drives a distinct spatiotemporal pattern of MOR activation and trafficking. The overall conclusion is that DFNZ (a PGP/BCRP substrate with constrained brain occupancy) can deliver effective analgesia with fewer classical opioid adverse effects, making it an intriguing candidate for further development, including potential sustained-release formulations for opioid-maintenance therapy.
Key Points
- FNZ and DFNZ are highly selective MOR superagonists with supramaximal efficacy in G-protein and β-arrestin recruitment assays.
- FNZ is rapidly metabolised to DFNZ; FNZ shows fast brain entry (detectable by PET), whereas DFNZ has impaired brain penetrance due to efflux by PGP and BCRP.
- Cryo-EM (2.3 Å) reveals the FNZ binding pose and structural determinants of MOR selectivity.
- DFNZ produces potent analgesia in acute and chronic pain models but, at therapeutic doses, does not trigger significant respiratory depression; it even increases brain oxygen modestly.
- Repeated DFNZ dosing did not induce tolerance, mechanical hypersensitivity or major reductions in MOR density in the nucleus accumbens.
- DFNZ causes substantially weaker precipitated withdrawal than morphine and weaker reinforcing effects in intravenous self-administration assays; it also reduces heroin intake when given prior to sessions.
- DFNZ evokes limited phasic dopamine release and preferentially promotes tonic dopamine signalling — likely explaining its low reinforcement and rapid extinction of drug-seeking behaviour.
- DFNZ shows reduced efficacy at MOR–GAL1 heteromers in vitro and VTA data indicate MOR–GAL1 interactions contribute to its weak dopaminergic effects.
- The distinct safety profile of DFNZ appears to stem from a combination of pharmacokinetic (limited brain occupancy) and pharmacodynamic (unique spatiotemporal MOR activation) properties.
- Authors propose DFNZ (or related nitazenes with similar profiles) merits further study as potential analgesics and as candidates for opioid-maintenance therapy with reduced respiratory risk.
Why should I read this?
Short answer: if you care about safer opioid medicines or addiction treatments, this is proper interesting. The paper flips the script — a superagonist that’s actually less dangerous in key ways — and backs it with structural, molecular and solid in vivo data. It’s heavy on experiments but the takeaway is neat: tweak chemistry so the drug either doesn’t get into the brain much or traffics receptors differently, and you can keep analgesia while cutting respiratory risk and reward signalling. Worth a skim if you follow pain pharmacology, and a closer read if you design drugs or study addiction biology.